

## Supplemental material

### Supplementary Table 1. Subgroup-analysis, with and without anthracyclines

A sub-analysis after propensity score matching.

**Abbreviations:** Anthra, anthracyclines; TZ, trastuzumab users; NT, trastuzumab non-users.

### Supplementary Figure 1. Cumulative incidence of post-operative heart failure within 18 months among women with early-stage breast cancer after propensity score (PS) matching. (Subgroup-analysis, with and without anthracyclines)

As a sub-analysis after PS matching, the cumulative incidence of post-operative heart failure within 18 months was presented for the trastuzumab (Trastuzumab, YES) and non-trastuzumab (Trastuzumab, NO) groups, subdivided into those with (Anthra, YES) and without anthracyclines (Anthra, NO).

**Supplementary Table 1. Subgroup-analysis, with and without anthracyclines**

Anthra[L01D]	Trastuzumab [L01XC03]			P-value
	Yes (TZ) (N=414)	No (NT) (N=828)	Total (N=1242)	
No	<b>months of CHF(18mo)</b>			0.03631
	Events/N	8/414	5/828	13/1242
	Hazard Ratio (95% CI)	3.10 (1.01 - 9.48)	Reference	
Yes	<b>months of CHF(18mo)</b>			0.00841
	Events/N	25/591	23/1182	48/1773
	Hazard Ratio (95% CI)	2.10 (1.19 - 3.70)	Reference	

<sup>1</sup>Logrank p-value;

**Supplementary Figure 1. Cumulative incidence of post-operative heart failure within 18 months in women with early-stage breast cancer. (Subgroup-analysis after PS match, with and without anthracyclines)**

